Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 18;145:106999. doi: 10.1016/j.vph.2022.106999

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Elsevier Inc. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 4 — Experimental validation with different techniques.

The discriminant performance of CD142-EV was experimentally validated by different techniques in patients with SARS-CoV2 infection: good prognosis (grey; n = 10) vs. poor prognosis (orange; n = 10). (A-B) CD142 activity per particle measured by ELISA (pM per 10⁹ particles), after EV isolation by ultracentrifugation (UC) or immunocapture (IC using beads covered by antibodies against CD9-CD63-CD81). (C) Correlation between CD142 activity per particle (pM) and CD142 MFI at flow cytometry after IC. (D) CD142-EV MFI after IC (direct staining after immuno-capture, using beads covered by antibodies against CD9-CD63-CD81). (E) Colocalization of tetraspanins (CD9-CD63-CD81) and CD142 was assessed by ExoView® R100 Analyzer. Data are reported for mean number of nanoparticles (NPs) per mm² for vesicles labelled with fluorochrome-conjugated antibodies against CD9-CD63-CD81 and for the double positive for CD9-CD63-CD81 and CD142.